

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 December 2022 (29.12.2022)



(10) International Publication Number
WO 2022/271557 A1

(51) International Patent Classification:

C07D 205/04 (2006.01) C07D 401/14 (2006.01)
C07D 209/48 (2006.01) C07C 309/00 (2006.01)

(21) International Application Number:

PCT/US2022/034028

(22) International Filing Date:

17 June 2022 (17.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/213,043 21 June 2021 (21.06.2021) US

(71) Applicant: **CELGENE CORPORATION** [US/US]; 86
Morris Avenue, Summit, NJ 07901 (US).

(72) Inventors: **CARRASQUILLO-FLORES, Ronald**; c/o
Bristol-Myers Squibb Company, Route 206 and Province
Line Road, Princeton, NJ 08543 (US). **CHEN, Jian**; c/o
Celgene Summit West, 556 Morris Avenue, Summit, NJ
07901 (US). **CORONA, Patrick**; c/o Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Prince-
ton, NJ 08543 (US). **DEL VALLE, David**; c/o Celgene
Summit West, 556 Morris Avenue, Summit, NJ 07901
(US). **DUNN, Robert, Francis**; c/o Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
NJ 08543 (US). **EMMANUEL, Megan**; c/o Bristol-My-
ers Squibb Company, Route 206 and Province Line Road,
Princeton, NJ 08543 (US). **FERRETTI, Antonio, C.**; c/
o Celgene Summit West, 556 Morris Avenue, Summit,
NJ 07901 (US). **HEID, Richard, Martin**; c/o Celgene
Summit West, 556 Morris Avenue, Summit, NJ 07901
(US). **KASSIM, Amude**; c/o Celgene Summit West, 556
Morris Avenue, Summit, NJ 07901 (US). **KOTHARE,
Mohit**; c/o Celgene Summit West, 556 Morris Avenue,


Summit, NJ 07901 (US). **LIU, Wei**; c/o Celgene Sum-
mit West, 556 Morris Avenue, Summit, NJ 07901 (US).
PURDUM, Geoffrey, Eugene; c/o Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
NJ 08543 (US). **RANGANATHAN, Krishnakumar**; c/o
Bristol-Myers Squibb Company, Route 206 and Province
Line Road, Princeton, NJ 08543 (US). **TAVARES-GRE-
CO, Paula, A.**; c/o Celgene Summit West, 556 Morris Av-
enue, Summit, NJ 07901 (US). **YONG, Kelvin, Hin-yeong**;
c/o Celgene Summit West, 556 Morris Avenue, Summit,
NJ 07901 (US). **YU, Yong**; c/o Celgene Summit West, 556
Morris Avenue, Summit, NJ 07901 (US). **ZHANG, Cheng-
min**; c/o Celgene Summit West, 556 Morris Avenue, Sum-
mit, NJ 07901 (US).

(74) Agent: **YANG, Kunyong** et al.; Jones Day, 250 Vesey
Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MOR-
PHOLINOAZETIDIN-1-YL) METHYL)BENZYL) AMINO)ISOINDOLINE-1,3-DIONE



(I)

(57) Abstract: Provided herein are processes for the preparation of (S)-2-(2,6- dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazeti-
din-1-yl) methyl) benzyl)amino)isoindoline-1, 3-dione, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue
thereof, which is useful for treating, preventing, and managing various disorders. Also provided are solid forms of various intermediates
and products obtained from the processes.

[Continued on next page]

WO 2022/271557 A1

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*